Humanigen Inc (fka HGENQ)

[cowtown jay]

As our latest Form 4 continues to disappear and reappear, even this morning, we may need to consider who the beneficiary of these shares may be. Baudax is still a contender. But another possibility may be that Novavax will receive these shares in a stock-for-stock merger agreement.

I say that for two new reasons. First, Novavax announced approval of their standard vaccine in South Korea just days ago.

https://ir.novavax.com/press-releases/Novavaxs-Updated-COVID-19-Vaccine-Receives-Emergency-Use-Authorization-in-the-Republic-of-Korea

And we know that S. Korea conducted a safety trial of Humanigen's lenzilumab some time ago.

https://ir.humanigen.com/English/news/news-details/2021/Humanigens-Partner-in-South-Korea-Receives-Ministry-of-Food-and-Drug-Safety-MFDS-Approval-to-Conduct-Phase-1-Study-of-Lenzilumab/default.aspx

In addition, the WHO's Emergency Use Listing (EUL) approval of the standard Novavax vaccine was based on non-clinical data.

However, in regards to Novavax's prototype vaccine, "In clinical trials, the most common adverse reactions associated with Novavax's prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise." It would likely have been the prototype vaccine that used lenz as an adjuvant.

It would be very exciting to see news in this regard, if my assumption about incorporating lenz in the prototype vaccine is correct.